Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.

@article{McCarthy2014TropomyosinRK,
  title={Tropomyosin receptor kinase inhibitors: a patent update 2009 - 2013.},
  author={Clive McCarthy and Edward Walker},
  journal={Expert opinion on therapeutic patents},
  year={2014},
  volume={24 7},
  pages={731-44}
}
INTRODUCTION Tropomyosin receptor kinases (Trks) are a family of three similar tyrosine kinases activated by peptide hormones of the neurotrophin family. The nerve growth factor antibody tanezumab has provided clinical proof of concept for inhibition of the TrkA pathway in pain. As an alternative modality, small-molecule inhibitors of the Trks have been pursued in recent years to probe the role of these neurotrophin pathways in pain, cancer and other indications. AREAS COVERED This paper… CONTINUE READING